Nautilus Biotechnology reports Q4 net loss $17.6M; platform launch delayed to late 2026; headcount cut 16%

Nautilus Biotechnology, Inc.

2024-FY EPS reported -$0.56

Q4 2024 operating expenses flat at $20.0M; FY2024 op. expenses $81.5M (+7% YoY).
Net loss Q4 $17.6M vs $17.0M YoY; FY2024 net loss $70.8M vs $63.7M YoY.
Proteome analysis platform commercial launch now expected late 2026 (previously undisclosed).
Headcount reduced ~16% to extend cash runway; cash $206.3M expected to fund operations through 2027.
Board changes: two directors not standing for re-election; Matthew McIlwain reclassified as Class I director; board size reduced to 7.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Altman

Director

NAUT · Nautilus Biotechnology, Inc.

Filed: February 27, 2025, 6:59 PM ET

each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors

Role change

Matthew McIlwain

Director

NAUT · Nautilus Biotechnology, Inc.

Filed: February 27, 2025, 6:59 PM ET

Matthew McIlwain agreed to resign as a Class II director, effective as of the opening of the polls for the election of Class I directors at the Annual Meeting, and to stand for election to the Board as a Class I director at the Annual Meeting

Departed

Vijay Pande

Director

NAUT · Nautilus Biotechnology, Inc.

Filed: February 27, 2025, 6:59 PM ET

each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Altman departed as Director at Nautilus Biotechnology, Inc..

Action: will not stand for re-election
Role: Director

Exact text from the filing

each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew McIlwain departed as Director at Nautilus Biotechnology, Inc..

Action: agreed to resign as a Class II director and to stand for election as a Class I director
Role: Director

Exact text from the filing

Matthew McIlwain agreed to resign as a Class II director, effective as of the opening of the polls for the election of Class I directors at the Annual Meeting, and to stand for election to the Board as a Class I director at the Annual Meeting

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Vijay Pande departed as Director at Nautilus Biotechnology, Inc..

Action: will not stand for re-election
Role: Director

Exact text from the filing

each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors

View on SEC.gov

Nautilus Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001808805-25-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.